Indication CINRYZE® (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years of age and older) with Hereditary Angioedema (HAE).

Other Treatment Options

Efficacy of CINRYZE in Adults and Adolescents

CINRYZE has been proven to reduce the frequency, severity, duration of attacks, and the number of days of swelling of hereditary angioedema (HAE) attacks in adults and adolescents.1

Adults and adolescents: Primary endpoint analysis

The efficacy of CINRYZE in preventing HAE attacks in adult and adolescent patients was evaluated based on the number of HAE attacks during the 12-week treatment period with CINRYZE compared with the number of attacks during the 12-week placebo treatment period.1

CINRYZE significantly reduced the mean number of HAE attacks vs. placebo (p<0.0001). The number (standard deviation) of HAE attacks was 6.1 (5.4) while taking CINRYZE vs. 12.7 (4.8) on placebo.1

CINRYZE has been proven to reduce the frequency of HAE attacks.1

In 20 out of 22 patients taking CINRYZE, attack frequency was reduced.1

Prevention of HAE attacks : clinical trial results by subject1

Subject Percent Reduction in Attack Frequency
1 100
2 100
3 100
4 100
5 90
6 88
7 84
8 83
9 78
10 76
11 60
Subject Percent Reduction in Attack Frequency
12 47
13 43
14 43
15 32
16 31
17 25
18 21
19 10
20 1
21 -8
22 -85

The effectiveness of CINRYZE prophylaxis in reducing the number of HAE attacks was variable among the 22 subjects in a controlled clinical trial.1

  • 20 patients experienced a reduction in attack frequency
    • Ranging from a 100% to 1% reduction in number of attacks
    • 4 patients experienced no attacks during a 12-week period
  • 2 patients experienced an increase in attack frequency
    • One patient showed an 8% increase in attacks
    • One patient showed an 85% increase in attacks

Study design

The pivotal trial was a randomized, double-blind, placebo-controlled, multicenter, crossover study of adults and adolescents designed to establish the safety (n=24) and efficacy (n=22) of CINRYZE prophylaxis in patients with a history of at least 2 HAE attacks per month. In addition to the primary efficacy analysis of attack frequency, secondary endpoints included the duration and severity of attacks and the number of days of swelling.1

Prevention with CINRYZE reduced the severity and duration of HAE attacks and days of swelling.1

Reduced attack severity
REDUCTION IN MEAN SEVERITY OF ATTACKS

Mean severity
of HAE attacks
(Score from 1 to 3)
3.0
2.5
2.0
1.5
1.0
0.5
0
Placebo1.9
CINRYZE1.3

(p<0.01)

Severity: 1=Mild, 2=Moderate, 3=Severe

CINRYZE significantly reduced the mean severity of HAE attacks vs. placebo (p<0.01).

  • Mean severity of HAE attacks (SD): CINRYZE 1.3 (0.85) vs. placebo 1.9 (0.36)
  • Mean treatment effect (placebo minus CINRYZE) was 0.58 (95% CI, 0.19, 0.97)

 

Reduced attack duration
REDUCTION IN MEAN DURATION OF ATTACKS

Mean duration of
HAE attacks (Days)
5
4
3
2
1
0
Placebo3.4
CINRYZE2.1

(p<0.01)

CINRYZE significantly reduced the mean duration of HAE attacks vs. placebo (p<0.01).

  • Mean duration of HAE attacks in days (SD): CINRYZE 2.1 (1.13) vs. placebo 3.4 (1.4)
  • Mean treatment effect (placebo minus CINRYZE) was 1.23 (95% CI, 0.49, 1.96)

 

Reduced number of days of swelling
REDUCTION IN DAYS OF SWELLING OVER 12 WEEKS

Mean number of
days of swelling
35
30
25
20
15
10
5
0
Placebo29.6
CINRYZE10.1

CINRYZE significantly reduced the mean number of days of swelling vs. placebo (p<0.01).

  • Days of swelling (SD): CINRYZE 10.1 (10.73) vs. placebo 29.6 (16.9)
  • Mean treatment effect (placebo minus CINRYZE) was 19.5 (95% CI, 11.94, 27.06)

You might also be interested in:

Dosing and Administration Safety Profile

Reference

  1. CINRYZE® (C1 esterase inhibitor [human]) Prescribing Information. Shire.

Definition: